

Jangik I Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5060379/publications.pdf>

Version: 2024-02-01

15
papers

254
citations

1162889

8
h-index

996849

15
g-index

15
all docs

15
docs citations

15
times ranked

382
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis. <i>Tuberculosis</i> , 2021, 127, 102052.	0.8	2
2	Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e521-e529.	0.2	3
3	Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. <i>Investigational New Drugs</i> , 2020, 38, 812-820.	1.2	33
4	Population pharmacokinetics of vactosertib, a new TGF- β 2 receptor type I TM inhibitor, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 173-183.	1.1	22
5	Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2020, 111, 417-426.	0.7	5
6	Development of an oral bentonite-based modified-release freeze-dried powder of vactosertib: Pharmacokinetics and anti-colitis activity in rodent models of ulcerative colitis. <i>International Journal of Pharmaceutics</i> , 2020, 578, 119103.	2.6	6
7	Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1006-1013.	0.7	11
8	Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e027940.	0.8	30
9	Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia. <i>Cancer Medicine</i> , 2018, 7, 1766-1773.	1.3	4
10	Antimicrobials for the treatment of drug-resistant <i>Acinetobacter baumannii</i> pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. <i>Critical Care</i> , 2017, 21, 319.	2.5	69
11	Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses. <i>Leukemia and Lymphoma</i> , 2016, 57, 1856-1864.	0.6	8
12	Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153502.	1.1	6
13	Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. <i>Tuberculosis</i> , 2015, 95, 54-59.	0.8	27
14	Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKK β inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2655-2660.	1.0	23
15	Effect of Ketoconazole on Lobeglitazone Pharmacokinetics in Korean Volunteers. <i>Clinical Therapeutics</i> , 2014, 36, 1064-1071.	1.1	5